Enveric Biosciences announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering a novel class of aminated tryptamine derivatives. These compounds, designed to address psychiatric and neurological disorders, are non-hallucinogenic psychedelic analogs and represent a first-in-class approach to mental health treatments. The patented molecules, developed through Enveric's proprietary discovery platform, promise improved safety and scalability, with applications for conditions like depression and anxiety without hallucinogenic side effects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.